Abstract
Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.
MeSH terms
-
Aged
-
Angioplasty, Balloon, Coronary*
-
Anticoagulants / administration & dosage*
-
Chi-Square Distribution
-
Coronary Artery Disease / blood
-
Coronary Artery Disease / therapy*
-
Female
-
Hirudins / administration & dosage*
-
Hirudins / analogs & derivatives*
-
Humans
-
Male
-
Middle Aged
-
Peptide Fragments / administration & dosage*
-
Recombinant Proteins / administration & dosage*
-
Reproducibility of Results
-
Retrospective Studies
-
Whole Blood Coagulation Time*
Substances
-
Anticoagulants
-
Hirudins
-
Peptide Fragments
-
Recombinant Proteins
-
bivalirudin